share_log

基蛋生物子公司年报延期披露至6月，或存在同业竞争问题

The disclosure of the annual report of the subsidiary Gidao Biotech was delayed until June, and there may be competition issues in the industry

Gelonghui Finance ·  Apr 27 14:02
Gelonghui, April 27 | Since the acquisition of Jingchuan Diagnostics, a company listed on the Shanghai Main Board in 2020, the two have continued to conflict as parent companies and subsidiaries for several years. On April 26, the subsidiary Jingchuan Diagnosis issued the “Notice of Resolutions of the 10th Meeting of the 3rd Board of Directors”. The announcement shows that on April 24, 2024, 5 directors of Jingchuan Diagnosis voted on 12 proposals, including the “Proposal on the Company's 2023 Annual Report and Summary” and the “Proposal on the Company's 2023 Capital Utilization Special Report”.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment